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Abstract
Introduction: The rising prevalence of Diabetes mellitus (DM) in high TB-
endemic countries may adversely affect sustainability of TB control since DM
constitutes a risk factor for development of active tuberculosis (TB). The impact of
DM on TB specific adaptive immune responses remains poorly addressed,
particularly in people living in Sub-Saharan countries. We performed a functional
characterization of TB specific cellular immune response in Tanzanian subjects
with active or latent Mycobacterium tuberculosis (Mtb) infection stratified by their
diabetic status.
Methods: HIV negative active TB patients (18 years) with Xpert MTB/RIF
positive pulmonary TB were included before starting TB treatment in Dar es
Salaam, Tanzania between April and December 2013. HIV negative healthy
controls latently infected with TB but without past TB history were also included.
Active and latent TB patients were stratified in two groups according to their
diabetic status. Peripheral BloodMononuclear cells were stimulated with either live
M. bovis BCG orMtb-specific peptide pools and analyzed by intracellular cytokine
staining and polychromatic flow cytometry.
Results:Our results show a lower frequency of IFN-gCD4þ T cells in patients with
active TB andDM compared to patients with active TB only after liveM. bovis BCG
(p¼ 0.04) but not afterMtb peptide pools re-stimulation. Irrespective of TB status,
level of glycaemia is selectively inversely correlated with IFN-g and TNF-aCD4þ T
cell production (p¼ 0.02 and p¼ 0.03) after live M. bovis BCG stimulation.
Conclusions: These results support the hypothesis that hyperglycaemia negatively
impacts antigen processing and/or presentation of whole mycobacteria delaying
secretion of key cytokines involved in TB immunity.
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Introduction
Diabetes mellitus (DM) increases the risk of active
tuberculosis (TB) by about threefold [1]. The recent rise
of type 2 DM prevalence in countries with pre-existing high
TB burden is expected to negatively impact current TB
control efforts [2]. The interaction between active TB and
DM suggests that host defence mechanisms for control of
Mycobacterium tuberculosis (Mtb) infection might be
impaired. Hyperglycaemia affects biological functions of
neutrophil granulocytes, macrophages and natural killer
cells, important constituents of the innate immune
system [3]. T cell-mediated immune responses are clearly
critical in the outcome of Mtb infection as demonstrated by
the marked susceptibility and reactivation of TB in HIV-co-
infected persons [4]. Defects in pro-inflammatory CD4þ T
cell polarization and cytokine production, particularly IFN-
g, are well-defined risk factors for mycobacteriosis [5]. The
immunological consequences of DM co-morbidity on TB
specific adaptive immunity has been evaluated in different
human studies with conflicting results [6]. Increased
production of Th1 cytokines following PBMC stimulation
with Mtb derived purified protein derivative in DM and TB
co-morbid patients compared to non-DM TB patients has
been observed in India, Mexico, and Texas, but not in
Indonesia [7–9].
To our knowledge, the immunological hallmarks under-
lying the negative impact of DM on TB disease progression
in sub-Saharan Africa have not been analyzed in depth. We
performed functional characterization of CD4þ T cells in
active and latent TB rigorously stratified by their diabetic
disease status. In contrast to previously published studies, we
stringently classified our DM cases based on three
recommended screening tests that were repeated 5 months
after TB treatment initiation to exclude patients with
transient stress-induced hyperglycaemia [10]. To compare
antigen-specific memory T cell frequencies across our study
participants, PBMC were stimulated with liveM. bovis BCG
(requiring antigen processing and presentation) or Mtb-
specific peptide pools (not depending on antigen processing
and presentation) followed by intracellular cytokine staining
and polychromatic flow cytometry. This comparison has to
our knowledge not been assessed systematically in TB DM
comorbidity studies.
Results and Discussion
Study cohort
We enrolled 26 volunteers with latent TB and 28 active TB
cases. Study participants with DM were significantly older
compared to normoglycaemic volunteers (Table 1). Overall,
94% of study participants were previously vaccinated with
BCG. Figure 1 depicts the distribution of participants with
latent TB and active TB according to their diabetic status.
Our study population was rigorously characterized for their
DM status based on three currently recommended screening
tests that were repeated 5 months after TB treatment
initiation. We therefore excluded all patients with transient
stress-induced hyperglycaemia that returned to normal after
TB treatment [10, 11]. Despite systematic screening of TB
patients for DM, the recruitment of patients with active TB
and DM was greatly impeded by exclusion of individuals
with HIV co-infection and of TB patients with transient
hyperglycaemia that does not represent true DM. Among
patients with active TB and DM co-morbidity, 5 out of 8
were treated for DM prior to TB diagnosis (4 were treated
with a combination of metformin and glibenclamide and 1
with insulin). Metformin, which is frequently used for DM
treatment, facilitates phagosome-lysosome fusion, and
enhances Mtb-specific immune response [12]. Glibencla-
mide that was also widely used in our study population has a
wide range of anti-inflammatory effect on the host
inflammasome [13]. All volunteers with latent TB and
DM comorbidity were reported to be under DM treatment at
the time of blood collection (1 was treated by metformin, 10
by a combination of metformin and glibenclamide and 1
received insulin). However, blood glycaemia levels were
clearly not controlled in these DM cases suggesting either
poor treatment adherence and/or interference of tuberculo-
sis itself with glycaemic control and treatment (Table 1).
Frequencies of IFN-g and TNF-a producing Mtb-
specific CD4þ T in relation to blood glucose levels
Following live M. bovis BCG stimulation of PBMC, we used
intracellular cytokine staining and polychromatic flow
cytometry to describe the quality and quantity of Mtb-
specific immune responses in our cohort (Supplementary
Fig. S1). We observed a reduced frequency of IFN-g
producing CD4þ T cells (p¼ 0.04) in TB cases with DM
compared to normoglycaemic TB cases (Fig. 2a). In contrast,
afterMtb-specific peptide pools stimulation, no difference in
cytokine producing CD4þ T cells frequencies was observed
between study groups (Fig. 2b). Polyclonal SEB stimulation
was performed as positive control on all samples analyzed
and no difference in frequencies of IFN-g, TNF-a, or IL-2
producing CD4þ T cells was measured (Fig. 2c).
Given the limiting sample size that may affect the power of
our study when patients are stratified, we next investigated
whether the level of intracellular cytokine production of
Mtb-specific CD4þ T cells would correlate with DM disease
severity irrespectively of TB disease status. An increase in
glycaemia was found to be negatively correlated with IFN-g
and TNF-a CD4þ T cells frequency after live M. bovis BCG
stimulation even after adjustment for age and sex (adjusted
p¼ 0.02 and 0.03, respectively). IL-2 production was not
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affected by the blood glucose levels (adjusted p¼ 0.17). In
contrast, no difference after Mtb-specific peptide pool or
SEB control stimulation was seen (Fig. 3).
Our study has several strengths when compared to
previously published data. First, our study population is very
well defined and has been followed longitudinally for 5
months [10]. Second, PBMC collection was performed prior
to TB treatment initiation since cellular immune responses
change rapidly under TB treatment [4]. Third, we have
studied PBMC instead of whole blood to circumvent
potential cofounders in relation to hyperglycaemia during
the whole blood assay [14]. Fourth, we compared two
different PBMC stimulation approaches using whole liveM.
bovis BCG side by side with ESAT6 and CFP10 peptide pools
stimulation. Despite more than 99.95% identity [15],
M. bovis, and its derivative, M. bovis BCG, underwent
significant genomic deletion events including virulence
factors when compared to most clinical M. tuberculosis
isolates. Comparative genome analysis showed that out of
483 experimentally verified human T-cell epitopes targeting
M. tuberculosis, 329 were present in the genome of the BCG
Danish strain used in this study [16]. Therefore, M. bovis
BCG expresses a substantial breadth of T-cell antigens
overlapping with M tuberculosis cellular immune targets.
Antigen processing of whole mycobacteria-derived antigens
for MHC class II presentation on the surface of antigen
presenting cells requires phagocytosis, processing, and
intracellular vesicular trafficking to allow the formation of
peptide-MHC-II complexes [17]. Soluble, exogenous syn-
thetic peptides can be directly loaded onto MHC class II
molecules present on the surface of antigen-presenting cells
and presented to CD4þ T cells [18, 19]. Head to head
comparison of synthetic peptides versus whole-mycobac-
teria to recall immune memory in vitro distinguishes
Table 1. Study population
Latent Mtb N¼ 14 Latent Mtb DM N¼ 12 Active TB N¼ 20 Active TB DM N¼ 8
N (%)/median (IQR) p value N (%)/median (IQR) p value
Age 35 (10) 45 (27) <0.001 28 (11) 57 (7) <0.001
Male sex 10 (71) 5 (42) 0.13 17 (85) 7 (88) 0.86
Low socio-economic status 3 (23) 2 (17) 0.69 7 (37) 3 (43) 0.78
Body mass index (kg/m2) 23.4 (5.5) 26.3 (8.8) 0.96 18.4 (4.3) 18.7 (3.6) 0.57
Under treatment for diabetes – 12 (100) – – 5 (63) –
TB symptom duration >1month – – – 15 (79) 6 (86) 0.70
Fasting capillary glucose (mmol/L) 4.8 (0.7) 10.1 (4.6) <0.001 5.0 (0.5) 18.3 (12) <0.001
Fasting plasma glucose (mmol/L) 5.1 (1.1) 16.4 (4.6) <0.001 5.1 (0.6) 20.7 (6.2) <0.001
Glycated Hemoglobin (%) 5.4 (0.6) 11.2 (3.4) <0.001 5.8 (0.7) 13.6 (4.5) <0.001
Latent Mtb: Mycobacterium tuberculosis latent infection defined as positive Mtb-specific Interferon-Gamma enzyme-linked immunospot
assay or positiveMtb-specific flow cytometry response/TB: tuberculosis/DM: diabetes mellitus. p value calculated with two-sidedWilcoxon–
Mann–Whitney or chi-square tests when appropriate.
Active tuberculosis
N=20
Diabetes mellitus
N=20
FCG and FPG≥7.0 mmol/l
+
2h-CG and 2-h-PG≥11.1 mmol/
+
HbA1c≥6.5%
Latent tuberculosis 
N=12
Active tuberculosis
N=8
Flow cytometry
results
N=19
Absence of diabetes mellitus
N=34
FCG and FPG<6.1 mmol/l
+
2h-CG and 2h-PG<7.8 mmol/l
Flow cytometry
results
N=12
Flow cytometry
results
N=7
Flow cytometry
results
N=12
Latent tuberculosis 
N=14
Figure 1. Flow chart of study participants and availability of ﬂow cytometry results. Deﬁnitions: FCG: fasting capillary glucose/FPG: fasting plasma
glucose/2h-CG: two-hours capillary glucose/2h-PG: 2-hplasma glucose/HbA1c: glycated haemoglobin.
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between ex vivo assessment of CD4þ T cell frequencies
directed against a specific antigen from the capacity of
antigen-presenting cells to uptake bacteria, process and
present bacteria-derived antigens to CD4þ T cells.
To our knowledge, one study examined the influence of
DM on CD4þ T cells responses from active TB cases after
stimulation with various Mtb antigens including purified
protein derivative or ESAT6 and CFP10. Contrasting with
our observations, higher frequencies of CD4þ T cells
expressing single or combinations of IFN-g, IL-2, and
TNF-a were found in active TB with DM compared to non-
diabetic TB cases, suggesting a sustained, strong adaptive
immune response in the presence of DM co-morbidity [7].
This study reported higher frequencies of CD4þ T cell
producing cytokines without stimulation (baseline) than
under antigen specific stimulation [7]. Our gating and
analytical strategy used here is fundamentally different since
T cell signals induced after antigen stimulation were actually
corrected by background signals observed in the negative
controls. We cannot exclude that the use of cryopreserved
PBMCs may have preferentially affected antigen presenta-
tion of monocytes from hyperglycaemic patients. Inclusion
of a viability dye in the flow cytometry analysis and gating
strategy indicated an overall excellent cell viability across all
samples (IQR: 98.6–95.8) which was not significantly
affected by DM status (IQR: 98.4–95.7). Another study
assessed secretion of IFN-g, IL-2, TNF-b, IL-4, IL-5, and IL-
10 into cell culture supernatants after stimulation with
purified mycobacterial antigens or whole-mycobacteria. No
significant differences among patients with active TB and
DM were described [20]. Collectively, these results and ours
suggested that Mtb-specific adaptive immunity is not
suppressed by DM but either unaffected or enhanced.
However, the fact that the negative correlation between
Figure 2. Frequencies of CD4þ T cells producing cytokines between the different study groups after: (a) liveM. bovis BCG stimulation; (b)Mtb-speciﬁc
peptide pool stimulation; (c) SEB stimulation.
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IFN-g and TNF-a CD4þ T cells frequency and DM severity
was observed under live M. bovis BCG stimulation is
consistent with the defective functions of antigen-presenting
cells among diabetics and patients with TB and DM [21–23]
and may promote delayed onset of the adaptive immune
system that could contribute to TB DM co-morbidity.
Different factors related to the host and pathogen genetics
and to the selection of the study participants make
comparison of the published results difficult. The study of
Kumar et al. was conducted in India and DM diagnosis was
based on glycated haemoglobin or random blood glucose
measured at TB diagnosis while Al-Attiyah et al. included TB
patients in Kuwait and defined DM using two blood glucose
measurements [7, 20]. In our study, patient stratification
according to DM was the most stringent possible using
repeated fasting glucose, an oral glucose tolerance test and
glycated haemoglobin assays. DM status was further
confirmed 5 months after TB treatment initiation to avoid
inclusion of patients presenting with transient stress-
induced hyperglycaemia [10]. In addition, all pre-DM
patients were excluded during enrollment. Most of our
diabetic participants were previously diagnosed and treated
for DM and did not take their DM treatment the day before
study inclusion. We were unable to trace this DM treatment
information in other published studies. We would like to
propose that our stringent DM classification could be
followed in future to clarify the interaction of DM and
immune responses to infectious agents across different study
populations. Futures studies should also describe the impact
of the different DM treatment medications on the Mtb
specific immune responses as they might contribute as host
directed therapy to tuberculosis containment [12, 24].
Concluding remarks
A significant negative correlation existed between increasing
levels of hyperglycaemia and the ability to measure IFN-g
and TNF-a producing CD4þ T cell responses following live
Figure 3. Dot-plot graphs of the frequencies of CD4þ T cells producing cytokines against fasting capillary glucose levels after: (a) live M. bovis BCG
stimulation; (b) Mycobacterium tuberculosis-speciﬁc peptide pool stimulation; (c) Staphylococcal enterotoxin B stimulation. Statistical analysis: Linear
regression adjusted for age and sex. The horizontal line represents themedian value of the logarithmic frequency of CD4þ T cells producing cytokines and
the vertical line represents the fasting glucose level cut-off for DM disease classiﬁcation. Patients with active tuberculosis: n¼ 28. Patients with latent
tuberculosis: n¼ 26.
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M. bovis BCG stimulation. This observation is in line with
experimental studies showing defective functions of antigen-
presenting cells among diabetics and with the reduced
interaction of Mtb with monocytes among patients with TB
and DM [21–23]. Our results clearly warrant further
investigation of the impact of blood glucose concentrations
on antigen processing and presentation of whole live
mycobacteria, notably in the context of the great potential
of testing Metformin as host-directed adjunct therapy
during TB drug treatment that may specifically compensate
for this defect [12].
Materials and Methods
Study design and setting
This prospective case-control study was nested within an
epidemiological study on the association between TB and
DM [10]. Study participants were recruited in Kinondoni
District in Dar es Salaam (Mwananyamala Regional
Hospital, Sinza Hospital, Magomeni Health Centre, and
Tandale Dispensary). We planned for recruitment of 20
patients per study group to arrive at a first overview of the
impact of DM on Mtb-specific adaptive immune responses.
Patients with active TB (with or without DM) were recruited
between April and December 2013 and latent TB cases (with
and without DM) between May and October 2013.
Study participants
Active TB patients (18 years) with microscopy smear positive
pulmonaryTBwere screened for inclusion.Patientswere eligible
if they were not on TB treatment, had a positive sputum Xpert
MTB/RIF (Cepheid, Sunnyvale) assay and were HIV negative
(Alere DetermineTM HIV-1/2 and Trinity Biotech Uni-goldTM
Recombigen1 HIV-1/2). Exclusion criteria were pregnancy
(positive urinary pregnancy screening test), first week of
lactation, any kind of immunosuppressive treatment or
condition during the last 6 months and severe anaemia
(<5 g/dl). Healthy controls were recruited among adults,
biologically unrelated to TB patients, living in Kinondoni
District. Controls with DMwere also recruited in the DM clinic
of Mwananyamala Regional Hospital. Eligibility criteria for
healthy controlswere:HIVnegative, nopast TBhistory, absence
of symptoms or signs of active TB or other acute infection or
major trauma within the last 3 months. Exclusion criteria were
identical to active TB cases. Healthy controls were classified as
latently infected withMtb based on positiveMtb-specific IFN-g
enzyme-linked immunospot assay (ELISPOT) or positive flow
cytometry result (frequency of IFN-g, TNF-a, or IL-2 CD4þ T
cells afterMtb-specific stimulation>0.03%and>2 timeshigher
than negative control). Healthy control samples without
evidence of latent TB infection were excluded from the analysis.
DM disease status was assessed before the start of TB
treatment using in parallel (1) the blood glucose testing
conducted after an overnight fast of 8 h (fasting capillary
glucose-FCG; GlucoPlusTM, Diabcare, a plasma-calibrated
glucometer which accuracy conformed to the International
Standardization Organization guidelines [25]); (2) 2-h
capillary glucose (2-hCG; standard 75-g oral glucose
tolerance testing); and (3) glycated hemoglobin HbA1c
(venipuncture whole blood; immuno-assay certified by the
National Glycohemoglobin Standardization Program and
insensitive to hemoglobinopathies (Tina-quant HbA1c Gen.
2 Cobas Integra 400, Roche Diagnostics, Rotkreuz,
Switzerland) [11, 25, 26]. DM was defined as repeated
measurements of7.0mmol/l for FCG,11.1mmol/l for 2-
hCG and6.5% for HbA1c and/or in the presence of history
and treatment for DM according to the standard American
Diabetes Association and World Health Organization
criteria [11, 27, 28]. DM status was confirmed after 5months
of TB treatment to exclude volunteers with transient
hyperglycaemia related stress induced hyperglycaemia [10].
Normal glycaemia was defined as FCG< 6.1mmol/l and 2-
hCG< 7.8mmol/l in the absence of treatment for DM. The
capillary glucose values were confirmed by plasma testing
(Cobas Integra 400 plus). All volunteers with pre-DM were
excluded.
Study procedures
Data and sample collection
Demographic characteristics, health history and symptoms,
socioeconomic status (indicators of education, occupation,
and wealth using factor analysis) were obtained. Complete
blood count was performed (Sysmex XS-800i automated
haematology analyzer). Data were entered directly into an
open data kit in a personal digital assistant with real-time
error, range and consistency checks [29]. Before TB
treatment initiation, PBMC were isolated and frozen to
808Cwithin 5 h of phlebotomy at a rate of18C/min using
Nalgene1Mr. Frosty1 Cryo 18C freezing containers before
transfer for cryo-preservation in temperature monitored
liquid nitrogen tanks.
Immunological assays
Immunological assays were performed after thawing and 5–
6 h resting of cryopreserved PBMC. For flow cytometry
assays, PBMC (1 106) were cultivated overnight in the
presence of Brefeldin A (BD GolgiPlug, Becton Dickinson,
USA) only (negative control), stimulated with Staphylococ-
cal enterotoxin B (SEB; Sigma, Germany; 200 ng/ml1)
(positive control), live M. bovis bacilli Calmette-Guerin
vaccine (20ml BCG Vaccine solution, Staten Serum
Institute) or Mtb specific peptide pools covering the
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10-kDa culture filtrate antigen (CFP10) and the 6-kDa early
secretory antigen target (ESAT6) protein sequences as
described previously (https://www.jpt.com) [30].
IFN-g ELISPOT assays
ELISPOT was performed as previously described [30].
ELISPOT result was defined positive when Mtb-specific
stimulation led to55 SFU per 106 cells and fourfold higher
than negative control.
Intracellular cytokine staining and flow cytometry analyses
Antigen and mitogen stimulated PBMC were incubated in
100ml PBS containing 1ml Aqua solution (LIVE/DEAD kit,
Invitrogen, USA), and then stained with antibodies specific for
CD3 (APC-H7, SK7, BD Biosciences, USA), CD4 (PE-CF594,
RPA-T4, BD Biosciences), CD8 (eFluor625NC, RPA-T8,
eBioscience), and CD45RA (BV711, 92430, Biolegend) before
fixation, and permeabilization with BD Cytofix/Cytoperm kit
(BD Biosciences). PBMCs were then stained with antibodies
directed against intracellular expressed IFN-g (AF700, B27, BD
Biosciences), TNF-a (PECy7, Mab11, BD Biosciences), IL-2
(PerCpCy5.5, MQ1-17H12, Biolegend), IL-10 (BV 421, JES3-
9D7, Biolegend), IL-17 (FITC, BL168, Biolegend), IL-4 (PE,
3010.211, BDBioscienecs), IL-5 (PE, TRFK5, Biolegend), IL-13
(PE, JES10-5A2, Biolegend), and IL-9 (Alexa647, MH9A4, BD
Biosciences). Cells were fixed and analysed on BD LSRII
apparatus equipped with 405, 488, 532, and 633nm lasers.
Gating strategy is shown on Figure S1. Only samples with a
cytokine response to SEB at least twice compared to the
unstimulated controlwere considered valid. Following limits of
quantitation described for antigen-specific T cell response
measured by intra-cellular detection of IFN-g, TNF-a, or IL-
2 [31], a polychromatic flow cytometry response was
considered valid when the frequency of cytokine-secreting
cells after live M. bovis BCG or Mtb-specific peptide pool
stimulationwas above 0.03%anddouble compared to negative
control values for IFN-g, TNF-a, or IL-2. As such, we retrieved
LTBI status from participants for which ELISPOT assay result
was missing or returned indeterminate (n¼ 12). Concordance
between both assays was high (85.4%). Among discordant
cases, four were assigned positive from ELIPOT results and
three from flow cytometry results. Among the latters, two
samples with 43 and 53 spot forming units already displayed
borderline results by ELISPOT.
Data analysis
Frequencies of CD4þ T cells producing cytokines as well as
quantitative cytokine responses were adjusted by subtracting
the background level (negative control).
Only cytokines with a flow cytometry responder’s
frequency 50% in at least one study group were kept in
subsequent analyses (i.e., IL4/5/13, IL-9, and IL-10 were
excluded).
Log transformed frequencies of CD4þ T cells producing
cytokines were analyzed across all participants according to
fasting glycaemia by linear regression after adjustment for
age and sex. HbA1c results were not considered as they
appeared to overestimate DM prevalence in this TB
population characterized by high prevalence of anemia
and hemoglobinopathies [10].
Statistical analyses were performed using Stata software
(StataCorp, College Station, TX, version 12), RStudio
(version 0.99.491) and GraphPad Prism 6.
Availability of Data and Material
The datasets generated and analyzed during the current
study are available from the corresponding author on
reasonable request.
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